gemcitabine has been researched along with nutlin-3a in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dobbelstein, M; Kranz, D | 1 |
| Chen, X; Jiang, H; Liu, L; Lu, Z; Meng, X; Song, X; Wang, J; Zheng, T | 1 |
| Algül, H; Conradt, L; Henrich, A; Krämer, OH; Lesina, M; Reichert, M; Saur, D; Schmid, RM; Schneider, G; Wirth, M | 1 |
| Abujamra, AL; Alemar, B; Ashton-Prolla, P; de Farias, CB; Giacomazzi, J; Hainaut, P; Hautefeuille, A; Izetti, P; Lenz, G; Osvaldt, AB; Roesler, R; Schwartsmann, G | 1 |
| Dobbelstein, M; Li, Y; Saini, P; Sriraman, A | 1 |
| Li, Y; Liu, J; Liu, Y; Ou, W; Su, F; Wang, R; Wang, X; Wu, Q; Zheng, J | 1 |
6 other study(ies) available for gemcitabine and nutlin-3a
| Article | Year |
|---|---|
Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Cytoprotection; Deoxycytidine; DNA, Neoplasm; Doxorubicin; Flow Cytometry; Gemcitabine; Genes, p53; Humans; Imidazoles; Keratinocytes; Mutation; Piperazines; Proto-Oncogene Proteins c-mdm2; S Phase | 2006 |
Disruption of p73-MDM2 binding synergizes with gemcitabine to induce apoptosis in HuCCT1 cholangiocarcinoma cell line with p53 mutation.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bile Duct Neoplasms; Blotting, Western; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; DNA-Binding Proteins; Drug Synergism; Drug Therapy, Combination; Gemcitabine; Humans; Imidazoles; Immunoprecipitation; Mutation; Nuclear Proteins; Piperazines; Proto-Oncogene Proteins c-mdm2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2010 |
Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death.
Topics: Amino Acid Chloromethyl Ketones; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Deoxycytidine; Disease Models, Animal; DNA Damage; Doxorubicin; Drug Synergism; Etoposide; Gemcitabine; Imidazoles; Immunohistochemistry; Immunoprecipitation; Indoles; Mice; Pancreatic Neoplasms; Piperazines; Proto-Oncogene Proteins c-mdm2; Pyrrolidinones; Topoisomerase II Inhibitors | 2013 |
PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Boronic Acids; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Imidazoles; Mutation; Pancreatic Neoplasms; Piperazines; Pyrazines; Quinazolines; RNA, Small Interfering; Tumor Suppressor Protein p53 | 2014 |
Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors.
Topics: Caspases; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Survival; Deoxycytidine; Enzyme Activation; Flow Cytometry; Gemcitabine; HCT116 Cells; Histones; Humans; Imidazoles; Immunoblotting; Microscopy, Confocal; Mitosis; Mutation; Nuclear Proteins; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-mdm2; Pyrazoles; Pyrimidines; Pyrimidinones; Tumor Suppressor Protein p53 | 2015 |
Nutlin-3 reverses the epithelial-mesenchymal transition in gemcitabine-resistant hepatocellular carcinoma cells.
Topics: Apoptosis; Cadherins; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Deoxycytidine; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gemcitabine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Imidazoles; Liver Neoplasms; Neoplasm Invasiveness; Piperazines; Smad2 Protein; Snail Family Transcription Factors; Tumor Suppressor Protein p53; Vimentin | 2016 |